Dr. Solomon Steiner, Chief Executive Officer and Chairman of Biodel, Inc., presides over the Closing bell.
April 22, 2008 - Biodel, Inc. [BIOD]
About this Marketsite Event:
Dr. Solomon Steiner, Chief Executive Officer and Chairman of Biodel, Inc., presides over the Closing bell in celebration of the company's one year listing anniversary.
About this Event:
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(tm) technology, which reformulates existing FDA-approved peptide drugs. The Company's lead product candidate, VIAject(tm), is an ultra rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(tm) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(tm), a sublingual tablet formulation of insulin in the Phase I stage of clinical testing, and two pre-clinical osteoporosis product candidates.
For further information regarding Biodel, please visit www.biodel.com
Press Inquiries Only:
Organizations interested in obtaining NASDAQ-listed company bell ringing ceremony photographs for press purposes, must first receive approval from the listed company before requesting photographs from NASDAQ. Please provide the company contact information from whom you received approval to Jolene Libretto at
jolene.libretto@nasdaq.com. Kindly credit © 2008, The Nasdaq Stock Market, Inc. Reprinted with permission.
Other Photography Inquiries:
For all other photography inquiries, please contact NASDAQ’s photographer, Rob Tannenbaum at
rob.tannenbaum@nasdaq.com.
© Copyright 2008, The NASDAQ Stock Market, Inc.
Reprinted with the permission of The Nasdaq Stock Market, Inc.
